Valcyte 450 mg Oral Tablet
RxNorm 284587
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 284587 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Valcyte 450 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SYPrescribable
Synonym (SY):
Valcyte 450 mg (valganciclovir hydrochloride 496.3 mg) Oral Tablet
(Atom ID: 2992811)
TMSYPrescribable
Tall Man Lettering Synonym (TMSY):
Valcyte 450 mg (valGANciclovir hydrochloride 496.3 mg) Oral Tablet
(Atom ID: 3741556)
PSNPrescribable
Prescribable Name (PSN):
Valcyte 450 mg Oral Tablet
(Atom ID: 6364314)
SYPrescribable
Synonym (SY):
Valcyte 450 mg Oral Tablet
(Atom ID: 2961204)
SBDPrescribable
Semantic Branded Drug (SBD):
Valganciclovir 450 mg Oral Tablet [Valcyte]
(Atom ID: 2961203)
TMSYPrescribable
Tall Man Lettering Synonym (TMSY):
ValGANciclovir 450 mg Oral Tablet [Valcyte]
(Atom ID: 3736229)
Patient Education
Valganciclovir
Valganciclovir is used to treat cytomegalovirus (CMV) retinitis (eye infection that can cause blindness) in people who have acquired immunodeficiency syndrome (AIDS). Valganciclovir is also used to prevent cytomegalovirus (CMV) disease in people who have received a heart, kidney, or kidney-pancreas transplant and who have a chance of getting CMV disease. Valganciclovir is in a class of medications called antivirals. It works by preventing the spread of CMV disease or slowing the growth of CMV.
[Learn More]
* Please review the disclaimer below.